ArticleFrontiers in surgery2026
Hemodynamic resilience and enhanced early recovery with fospropofol versus propofol in high-BMI patients undergoing surgery: a randomised controlled trial.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with elevated body mass index (BMI) are particularly susceptible to propofol-induced hypotension during anesthesia induction. Fospropofol, a water-soluble prodrug of propofol, may confer hemodynamic advantages through gradual release kinetics, yet its profile in high-BMI patients remains incompletely characterized. Methods: This pre-specified secondary analysis of a randomised controlled trial (ChiCTR2500101725) enrolled 120 patients with BMI ≥28 kg/m² scheduled for elective surgery, randomised to fospropofol (FOS, Results: Hypotension incidence was 30.0% (FOS) vs. 71.7% (PRO) [RR 2.39, 95% CI 1.57-3.63; Conclusions: Fospropofol demonstrated superior hemodynamic stability during the pre-incision phase and faster early recovery compared with propofol in high-BMI patients, particularly in abdominal surgical procedures. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=253889, identifier ChiCTR2500101725 (registered 29 April 2025).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.